Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label exploratory study of dupilumab on skin barrier function in Chinese patients with atopic dermatitis
2024-000164-37Phase 4
- Sponsor
- Sanofi
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in atopic dermatitis (AD), sponsored by Sanofi. Primary endpoint: Primary: Percent change from baseline in TEWL after 5 STS on lesional skin at Week 16.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-000164-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000164-37.